<DOC>
	<DOC>NCT00696787</DOC>
	<brief_summary>The purpose of this study is to evaluate if DVS SR is safe and effective in the treatment of pain associated with fibromyalgia syndrome, and if so to identify the efficacious doses.</brief_summary>
	<brief_title>A Study Evaluating Desvenlafaxine Sustained Release (DVS SR) in Adult Female Outpatients With Fibromyalgia</brief_title>
	<detailed_description />
	<mesh_term>Fibromyalgia</mesh_term>
	<mesh_term>Myofascial Pain Syndromes</mesh_term>
	<mesh_term>Desvenlafaxine Succinate</mesh_term>
	<mesh_term>Pregabalin</mesh_term>
	<criteria>Fibromyalgia diagnosed according to 1990 American College of Rheumatology criteria Unstable medical or psychological conditions that would compromise the subject's safety or put the subject at greater risk during study participation Other painful conditions that may confound the diagnosis or assessment of fibromyalgia Treatment with other drugs for fibromyalgia with 14 days of study start or during the study</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
</DOC>